Abbott Laboratories ABT
Price alert —
Sign in to get a one-time email the moment ABT crosses your price. Free accounts included.
Sign in / create a free accountAbbott Laboratories is a healthcare company listed in the US.
ABT last traded at $100.68, up 1.9% on the day; that's in the middle part of its 52-week range ($81.97–$122.49). Right now it's stretched well above its recent average — moves this fast often cool off or give some back.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
On the latest daily bar, momentum sits mid-range (RSI 67), the trend is quiet (ADX 22), and volume is about normal (1.3×). On the business side, revenue is growing 8% year over year and the business keeps about 14 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $59.90 (fair range $60–$76); today's price sits 65% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Debt/equity 0.65 (antifragile)
- ✓ Positive retained earnings
- ✓ Gross margin 57% (pricing power)
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.92 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~15% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
ABT is a $156.5 billion company, priced at 28× last year's earnings.